- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Eris Lifesciences Limited — Important, 23-06-2026: Updates
23-06-2026 | 04:13 pm
23-06-2026 | 04:13 pm
Eris Lifesciences reports robust growth: FY26 revenue 3,129 Cr, EBITDA 1,120 Cr. Strategic acquisitions (4,300+ Cr) and strong R&D drive expansion in Anti-Diabetes (6% share) & Insulins (16%). Sundae Gx Semaglutide launched strong. EU-GMP observations noted; minimal impact on existing business. FY27 revenue guided 18-20%.
No comments yet. Be the first to comment!